<!--
title: Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
description: DOI:https://doi.org/10.1016/S0140-6736(22)00090-3
published: true
date: 2022-01-24T10:22:08.931Z
tags: #vaccine, #sarscov2, #mrna, #breakthrough, #infections, #efficiacy, #dose, #reduction, #vaccines, #sars-cov2, #omicron, #booster
editor: ckeditor
dateCreated: 2022-01-24T10:22:08.931Z
-->

<h1>Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose</h1>
<p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00090-3/fulltext#">Constanze Kuhlmann</a></p>
<p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00090-3/fulltext#">Carla Konstanze Mayer</a></p>
<p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00090-3/fulltext#">Mathilda Claassen</a></p>
<p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00090-3/fulltext#">Tongai Maponga</a></p>
<p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00090-3/fulltext#">Wendy A Burgers</a></p>
<p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00090-3/fulltext#">Roanne Keeton</a></p>
<ul>
  <li>et al.</li>
</ul>
<p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00090-3/fulltext#">Show all authors</a></p>
<p>Published:January 18, 2022DOI:<a href="https://doi.org/10.1016/S0140-6736(22)00090-3">https://doi.org/10.1016/S0140-6736(22)00090-3</a></p>
<p>&nbsp;</p>
<p>In-vitro data suggest lower titres of neutralising antibodies against omicron compared to other SARS-CoV-2 lineages following BNT162b2 vaccination but increased titres after a third dose, supporting calls for booster doses while the omicron variant appears to be spreading globally. Our study, however, demonstrates insufficient prevention of symptomatic infection in otherwise healthy individuals who had received three doses of COVID-19 mRNA vaccines.</p>
<p>These findings support the need for updated vaccines to provide better protection against symptomatic infection with omicron and emphasise that non-pharmaceutical measures should be maintained. Encouragingly, early data from South Africa suggest maintained if reduced effectiveness of the BNT162b2 vaccine against hospital admission.</p>
<p>Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00090-3/fulltext</p>
